Literature DB >> 9798660

Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients.

W G Finn1, N E Kay, S H Kroft, S Church, L C Peterson.   

Abstract

Although karyotypic abnormalities are well documented in B-cell chronic lymphocytic leukemia (B-CLL), few sequential cytogenetic studies have been done. In this study, peripheral blood lymphocytes from fifty-one patients with B-CLL were sequentially karyotyped over a mean interval of 13.8 months (range, one to 51 months). Cytogenetic clones were detected in 33/51 patients (66%) on initial study, including 17 patients with structural abnormalities of chromosome 13q14, and three patients with trisomy 12. Karyotypic evolution was documented in 22/51 patients (43%). The most common secondarily acquired chromosome aberrations were structural abnormalities of the long arm of chromosome 6 involving the region of 6q21-q24 (six patients). Four patients each had acquired structural abnormalities of 1q, 3p, 12q, and 13q. Disease progression, as measured by advance in Rai stage or death from the disease, was observed more often in the clonal evolution group than in the karyotypically stable group (11/22 vs. 5/29; P = 0.017). Patients with secondary abnormalities of 6q had a significantly decreased progression-free survival interval compared with other patients in the study (P = .023). The authors conclude that clonal karyotypic evolution is common in B-CLL, and that clonal evolution correlates with clinical disease progression. Furthermore, the poor outcomes previously attributed to CLL with 6q abnormalities may be related to the clonal acquisition of these abnormalities over time. Future studies should focus on the relevant genetic events underlying the clinical progression observed with karyotypic evolution of B-CLL.

Entities:  

Mesh:

Year:  1998        PMID: 9798660     DOI: 10.1002/(sici)1096-8652(199811)59:3<223::aid-ajh7>3.0.co;2-y

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Anti-apoptotic protein BCL2 down-regulates DNA end joining in cancer cells.

Authors:  Tadi Satish Kumar; Vijayalakshmi Kari; Bibha Choudhary; Mridula Nambiar; T S Akila; Sathees C Raghavan
Journal:  J Biol Chem       Date:  2010-08-10       Impact factor: 5.157

2.  Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.

Authors:  Rebeqa Gunnarsson; Larry Mansouri; Anders Isaksson; Hanna Göransson; Nicola Cahill; Mattias Jansson; Markus Rasmussen; Jeanette Lundin; Stefan Norin; Anne Mette Buhl; Karin Ekström Smedby; Henrik Hjalgrim; Karin Karlsson; Jesper Jurlander; Christian Geisler; Gunnar Juliusson; Richard Rosenquist
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

3.  Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.

Authors:  E Braggio; N E Kay; S VanWier; R C Tschumper; S Smoley; J E Eckel-Passow; T Sassoon; M Barrett; D L Van Dyke; J C Byrd; D F Jelinek; T D Shanafelt; R Fonseca
Journal:  Leukemia       Date:  2012-01-20       Impact factor: 11.528

Review 4.  Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma.

Authors:  Gordon W Dewald
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 5.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

6.  Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.

Authors:  Marc DE Braekeleer; Corine Tous; Nadia Guéganic; Marie-Josée LE Bris; Audrey Basinko; Frédéric Morel; Nathalie Douet-Guilbert
Journal:  Mol Clin Oncol       Date:  2016-02-26

Review 7.  Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia.

Authors:  Nitin Jain; Nicole Lamanna
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

Review 8.  Chromothripsis in Chronic Lymphocytic Leukemia: A Driving Force of Genome Instability.

Authors:  Kristyna Zavacka; Karla Plevova
Journal:  Front Oncol       Date:  2021-11-26       Impact factor: 6.244

9.  Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis.

Authors:  L Bassaganyas; S Beà; G Escaramís; C Tornador; I Salaverria; L Zapata; O Drechsel; P G Ferreira; B Rodriguez-Santiago; J M C Tubio; A Navarro; D Martín-García; C López; A Martínez-Trillos; A López-Guillermo; M Gut; S Ossowski; C López-Otín; E Campo; X Estivill
Journal:  Leukemia       Date:  2013-04-24       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.